Nuveen LLC Takes Position in Bicara Therapeutics Inc. $BCAX

Nuveen LLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 25,028 shares of the company’s stock, valued at approximately $326,000.

Other large investors also recently bought and sold shares of the company. California State Teachers Retirement System purchased a new position in Bicara Therapeutics during the 4th quarter valued at about $25,000. BNP Paribas Financial Markets purchased a new position in Bicara Therapeutics in the fourth quarter worth about $32,000. CWM LLC purchased a new position in Bicara Therapeutics in the first quarter worth about $29,000. New York State Common Retirement Fund purchased a new position in Bicara Therapeutics in the first quarter worth about $52,000. Finally, Avanza Fonder AB purchased a new position in Bicara Therapeutics in the first quarter worth about $88,000.

Analyst Ratings Changes

BCAX has been the subject of several research reports. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. Wells Fargo & Company raised shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price objective for the company in a report on Friday, May 23rd. Wall Street Zen cut shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Finally, Piper Sandler initiated coverage on shares of Bicara Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $32.25.

Bicara Therapeutics Price Performance

BCAX opened at $12.06 on Friday. The firm has a market cap of $657.99 million and a P/E ratio of -3.80. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $28.09. The company has a 50 day simple moving average of $10.94 and a two-hundred day simple moving average of $11.84.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. Equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.